Biotron (ASX:BIT) Institutional Ownership : 0.04% (As of Apr. 15, 2025)

View and export this data going back to 2001. Start your Free Trial

What is Biotron Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biotron's institutional ownership is 0.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biotron's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biotron's Float Percentage Of Total Shares Outstanding is 0.00%.

Biotron Institutional Ownership Historical Data

The historical data trend for Biotron's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Institutional Ownership Chart

Biotron Historical Data

The historical data trend for Biotron can be seen below:

	2023-12-31
Institutional Ownership	0.04

Biotron Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Biotron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (ASX:BIT) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BITRF:USA

Address

56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113

Website

https://www.biotron.com.au

Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron Headlines

From GuruFocus

BlackRock Multi-Sector Income Trust's Dividend Analysis

By GuruFocus Research • 10-13-2023

BlackRock Announces Fiscal Year End Change for BlackRock Multi-Sector Income Trust (BIT)

By Business Wire Business Wire • 06-01-2023